TY - JOUR
T1 - Estimating prevalence for limb-girdle muscular dystrophy based on public sequencing databases
AU - Liu, Wei
AU - Pajusalu, Sander
AU - Lake, Nicole J.
AU - Zhou, Geyu
AU - Ioannidis, Nilah
AU - Mittal, Plavi
AU - Johnson, Nicholas E.
AU - Weihl, Conrad C.
AU - Williams, Bradley A.
AU - Albrecht, Douglas E.
AU - Rufibach, Laura E.
AU - Lek, Monkol
N1 - Funding Information:
N.J.L. is the recipient of a National Health and Medical Research Council (NHMRC) CJ Martin Early Career Fellowship and an American Australian Association scholarship. S.P. was supported by the Estonian Research Council grant (PUTJD827).
Publisher Copyright:
© 2019, American College of Medical Genetics and Genomics.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Purpose: Limb-girdle muscular dystrophies (LGMD) are a genetically heterogeneous category of autosomal inherited muscle diseases. Many genes causing LGMD have been identified, and clinical trials are beginning for treatment of some genetic subtypes. However, even with the gene-level mechanisms known, it is still difficult to get a robust and generalizable prevalence estimation for each subtype due to the limited amount of epidemiology data and the low incidence of LGMDs. Methods: Taking advantage of recently published exome and genome sequencing data from the general population, we used a Bayesian method to develop a robust disease prevalence estimator. Results: This method was applied to nine recessive LGMD subtypes. The estimated disease prevalence calculated by this method was largely comparable with published estimates from epidemiological studies; however, it highlighted instances of possible underdiagnosis for LGMD2B and 2L. Conclusion: The increasing size of aggregated population variant databases will allow for robust and reproducible prevalence estimates of recessive disease, which is critical for the strategic design and prioritization of clinical trials.
AB - Purpose: Limb-girdle muscular dystrophies (LGMD) are a genetically heterogeneous category of autosomal inherited muscle diseases. Many genes causing LGMD have been identified, and clinical trials are beginning for treatment of some genetic subtypes. However, even with the gene-level mechanisms known, it is still difficult to get a robust and generalizable prevalence estimation for each subtype due to the limited amount of epidemiology data and the low incidence of LGMDs. Methods: Taking advantage of recently published exome and genome sequencing data from the general population, we used a Bayesian method to develop a robust disease prevalence estimator. Results: This method was applied to nine recessive LGMD subtypes. The estimated disease prevalence calculated by this method was largely comparable with published estimates from epidemiological studies; however, it highlighted instances of possible underdiagnosis for LGMD2B and 2L. Conclusion: The increasing size of aggregated population variant databases will allow for robust and reproducible prevalence estimates of recessive disease, which is critical for the strategic design and prioritization of clinical trials.
KW - disease prevalence
KW - limb-girdle muscular dystrophy
KW - rare disease
UR - http://www.scopus.com/inward/record.url?scp=85066062369&partnerID=8YFLogxK
U2 - 10.1038/s41436-019-0544-8
DO - 10.1038/s41436-019-0544-8
M3 - Article
C2 - 31105274
AN - SCOPUS:85066062369
SN - 1098-3600
VL - 21
SP - 2512
EP - 2520
JO - Genetics in Medicine
JF - Genetics in Medicine
IS - 11
ER -